

BiVictriX Therapeutics Strengthens Board with US-Facing Appointment

Appointment of Dr Petter Veiby to the Board bolsters ADC expertise and expands investor reach in the US.

11 August 2025 – BiVictriX Therapeutics Ltd, today announces a strategic Board appointment that significantly enhances the Company’s scientific leadership and international reach.

Dr Petter Veiby has been appointed as a Non-Executive Director to the Board, bringing over 25 years of experience in oncology drug discovery, development, and strategic partnering.

“We are thrilled to welcome Petter to the team,” said Tiffany Thorn, CEO of BiVictriX. “His expertise in ADC development, translational science, and connections in US capital markets will be invaluable as we advance our bispecific ADC pipeline and deepen our footprint in the US. Petter has recently been involved in several successful financing rounds, backed by premier US-based investors, aligning with BiVictriX’s strategic ambitions in this key market.”

Dr Petter Veiby – Board Appointment

Dr Veiby currently serves as Chief Scientific Officer and Co-Founder of Attovia Therapeutics, an emerging US biotech that has raised \$255 million in the past 18 months from top-tier life science investors. His previous leadership roles span Takeda, Millennium, and Zai Lab, where he has built deep expertise in ADCs, bispecifics, and immune cell engagers.

As Global Head of Biotherapeutics at Takeda, Dr Veiby oversaw the company’s biotherapeutic pipeline strategy, building capabilities through internal innovation and strategic partnerships. He played a central role in advancing Adcetris and several ADC molecules to the clinic as well strengthening Takeda’s early- to late-stage oncology portfolio.

“I’ve followed BiVictriX with interest for several years,” commented Dr Veiby. “I believe the Company is uniquely positioned at the forefront of bispecific ADC development, and I’m excited to contribute to its next stage of growth.”

This appointment marks a major milestone for BiVictriX as it continues to grow its leadership team and increase engagement with international investors and partners. The Company’s bispecific ADC platform is designed to precisely target cancer cells while sparing healthy tissue, offering a new class of therapies with enhanced safety and efficacy profiles.